• Bladder cancer: ipilimumab-heavy immunotherapy combo offers best response

    Updated results from CheckMate 032.

  • Human papillomavirus and the risk of urothelial carcinoma of the bladder

    Results from a case-control study.

  • Urothelial cancer: 2-year data support pembrolizumab over chemotherapy

    Long-term KEYNOTE-045 data maintain consistency.

  • FDA approves erdafitinib for bladder cancer

    Companion diagnostic test cleared to identify patients with susceptible FGFR mutations.

  • Draft guidance on transurethral laser ablation for bladder cancer

    The draft guideline is open for public comment until 18 April 2019

  • Bladder cancer: atezolizumab safe, effective in real-world study

    Findings from IMvigor211 are applicable to a broader, pretreated population.

  • MIBC: RC delay after NACT, TURBT tied to poorer survival

    Rural neighborhood and change in provider were associated with delays.

  • EAU 2019: early menopause linked to increased risk for bladder cancer
    EAU 2019: early menopause linked to increased risk for bladder cancer

    The association was notable primarily in smokers.

  • ASCO-SITC 2019—Lenvatinib + pembrolizumab yields 25% ORR in advanced urothelial cancer

    Phase 1b/2 findings warrant further study.

  • ASCO-GU 2019—Adjuvant chemotherapy + postop radiotherapy improves DFS, OS in locally advanced urothelial carcinoma

    Post-hoc analysis of phase 3 trial results.

  • Mediterranean diet tied to lower risk for bladder cancer

    Findings from BLEND study of 645,000 participants.

  • Urothelial cancer: VTE risk higher with gemcitabine/cisplatin

    SEER-Medicare analysis shows higher risk than MVAC and CarboG.

  • Electrically-stimulated intravesical chemotherapy for bladder cancer

    NICE issues new guidance on electrically-stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer

  • Bladder cancer: squamous histology carries worse prognosis

    No survival benefit observed for NACT with SCC histology.

  • Cancer breath test trial launched in Cambridge
    Cancer breath test trial launched in Cambridge

    Cancer Research UK announces the first UK trial of breath biopsy technology to detect multiple cancer types.

  • MIBC: NACT tops ACT for disease-free survival

    Complete pathologic response is a significant prognostic factor.

  • MIBC: 2-month or more NACT delay tied to upstaging

    RC should be performed within 7 months from initial diagnosis.

  • Load more